摘要
多发性骨髓瘤(multiple myeloma,MM)的主要临床表现之一是骨髓瘤骨病(myeloma bone disease,MBD),其以进行性溶骨为特征。近年来的研究发现,一种与胚胎发生及肿瘤发展密切相关的糖蛋白Dickkopf(DKK1)能够抑制Wnt信号转导通路,通过多种途径抑制成骨细胞、激活破骨细胞,从而在MBD的发生中起重要作用。基于此机制的MBD靶向治疗措施正在探索中,DKK1的中和抗体、蛋白酶体抑制剂、疫苗以及调节因子等治疗已初显疗效。
Myeloma bone disease（MBD） with the characteristic of progressing osteolysis,is one of the main clinical manifestations of multiple myeloma（MM）.In recent years,it was revealed that a kind of glycoprotein-Dickkopf（DKK1） associated with embryonic development and tumor progression can inhibit the Wnt signal pathway.The DKK1 efficacy in inhibiting the steoblasts and activating the osteoclasts appears to play an important role in MBD.The ongoing MBD-targeting therapies involving DKK1 neutralizing antibody,proteasome inhibitor,vaccine and regulatory factor on the basis of this mechanism have shown some benefit for MBD.
出处
《肿瘤》
CAS
CSCD
北大核心
2011年第3期273-276,共4页
Tumor
基金
国家自然科学基金资助项目(编号:30700337)
关键词
多发性骨髓瘤
骨髓瘤骨病
肿瘤治疗方案
糖蛋白类
Multiple myeloma
Myeloma bone disease
Antineoplastic protocols
Glycoproteins
